Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae
Journal of Interferon & Cytokine Research · 2022-08 · 42 (8) · 352-368
DOI: 10.1089/jir.2021.0222 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Interferon & Cytokine Research, online erschienen am 18.08.2022. Verfasst von Gustavo Ramírez-Martínez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico. Hauptthemen laut MEDLINE: COVID-19, Matrix Metalloproteinases, Transforming Growth Factor beta. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The costs of coronavirus disease 2019 (COVID-19) are devastating. With millions of deaths worldwide, specific serological biomarkers, antiviral agents, and novel therapies are urgently required to reduce the disease burden. For these purposes, a profound understanding of the pathobiology of COVID-19 is mandatory. Notably, the study of immunity against other respiratory infections has generated reference knowledge to comprehend the paradox of the COVID-19 pathogenesis. Past studies point to a complex interplay between cytokines and other factors mediating wound healing and extracellular matrix (ECM) remodeling that results in exacerbated inflammation, tissue injury, severe manifestations, and a sequela of respiratory infections. This review provides an overview of the immunological process elicited after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Also, we analyzed available data about the participation of matrix metalloproteinases (MMPs) and transforming growth factor-beta (TGF-β) in immune responses of the lungs. Furthermore, we discuss their possible implications in severe COVID-19 and sequela, including pulmonary fibrosis, and remark on the potential of these molecules as biomarkers for diagnosis, prognosis, and treatment of convalescent COVID-19 patients. Our review provides a theoretical framework for future research aimed to discover molecular hallmarks that, combined with clinical features, could serve as therapeutic targets and reliable biomarkers of the different clinical forms of COVID-19, including convalescence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas," Mexico City, Mexico.
- Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Mexico City, Mexico.
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
ORCID-Profile: Gustavo Ramírez-Martínez, José Alberto Choreño-Parra
Zitieren
APA
Ramírez-Martínez, G., Jiménez-Álvarez, L. A., Cruz-Lagunas, A., Ignacio-Cortés, S., Gómez-García, I. A., Rodríguez-Reyna, T. S., Choreño-Parra, J. A., & Zúñiga, J. (2022). Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae. Journal of Interferon & Cytokine Research, 42(8), 352-368. https://doi.org/10.1089/jir.2021.0222
Vancouver
Ramírez-Martínez G, Jiménez-Álvarez LA, Cruz-Lagunas A, Ignacio-Cortés S, Gómez-García IA, Rodríguez-Reyna TS, et al. Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae. Journal of Interferon & Cytokine Research. 2022;42(8):352-368. doi:10.1089/jir.2021.0222
BibTeX
@article{RamrezMartnez2022,
author = {Ramírez-Martínez, Gustavo and Jiménez-Álvarez, Luis Armando and Cruz-Lagunas, Alfredo and Ignacio-Cortés, Sergio and Gómez-García, Itzel Alejandra and Rodríguez-Reyna, Tatiana Sofia and Choreño-Parra, José Alberto and Zúñiga, Joaquín},
title = {Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae},
journal = {Journal of Interferon & Cytokine Research},
year = {2022},
volume = {42},
number = {8},
pages = {352--368},
doi = {10.1089/jir.2021.0222}
}
EUVIMED